{"id":"aspirin-clopidogrel-rivaroxaban","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding (major and minor)"},{"rate":null,"effect":"Gastrointestinal bleeding"},{"rate":null,"effect":"Intracranial hemorrhage"},{"rate":null,"effect":"Dyspepsia"},{"rate":null,"effect":"Anemia"}]},"_chembl":{"chemblId":"CHEMBL198362","moleculeType":"Small molecule","molecularWeight":"435.89"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aspirin irreversibly inhibits cyclooxygenase to prevent thromboxane A2 production, clopidogrel blocks P2Y12 adenosine diphosphate receptors on platelets, and rivaroxaban is a direct Factor Xa inhibitor that prevents thrombin generation. Together, these agents provide dual antiplatelet therapy combined with anticoagulation for enhanced thromboprophylaxis in high-risk cardiovascular patients.","oneSentence":"This triple anticoagulant/antiplatelet combination inhibits blood clotting through multiple pathways: aspirin and clopidogrel block platelet aggregation, while rivaroxaban inhibits Factor Xa in the coagulation cascade.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:42:43.123Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome with high thrombotic risk"},{"name":"Secondary prevention of cardiovascular events in post-acute coronary syndrome patients"}]},"trialDetails":[{"nctId":"NCT03568890","phase":"PHASE4","title":"Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec","startDate":"2018-09-01","conditions":"Left Atrial Appendage Closure, Thrombosis, Stroke","enrollment":510},{"nctId":"NCT05387954","phase":"PHASE3","title":"PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-07-07","conditions":"Cryptogenic Ischemic Stroke, Patent Foramen Ovale","enrollment":792},{"nctId":"NCT05047172","phase":"PHASE3","title":"Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2022-08-02","conditions":"Intracranial Arteriosclerosis, Stroke","enrollment":1683},{"nctId":"NCT06901466","phase":"PHASE4","title":"STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients With an Indication for Oral Anticoagulant","status":"RECRUITING","sponsor":"Chinese Academy of Medical Sciences, Fuwai Hospital","startDate":"2025-06-13","conditions":"Mitral Regurgitation","enrollment":880},{"nctId":"NCT07358416","phase":"","title":"Complications and Antiplatelet and Anticoagulant Therapy in Vascular Surgery.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Petrovsky National Research Centre of Surgery","startDate":"2025-05-01","conditions":"Thrombosis, Bleeding, Cerebral Hypoxia During and/or Resulting From A Procedure","enrollment":500},{"nctId":"NCT04045665","phase":"PHASE3","title":"Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2019-12-13","conditions":"Atrial Fibrillation, Stroke, Bleeding","enrollment":3200},{"nctId":"NCT03463317","phase":"PHASE4","title":"Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2018-02-28","conditions":"Atrial Fibrillation","enrollment":912},{"nctId":"NCT07195812","phase":"PHASE4","title":"Rivaroxaban for Slow Coronary Flow After PCI in STEMI","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-10","conditions":"ST Elevation Myocardial Infarction, No-Reflow Phenomenon","enrollment":60},{"nctId":"NCT05907629","phase":"","title":"Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis- Magnetic Resonance Imaging","status":"RECRUITING","sponsor":"Yale University","startDate":"2024-06-24","conditions":"Stroke, Intracranial Atherosclerotic Stenosis (ICAS)","enrollment":300},{"nctId":"NCT05643651","phase":"PHASE4","title":"Rivaroxaban for Children Aged Over 2 Years With Giant Coronary Artery Aneurysms After Kawasaki Disease","status":"RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2025-06-01","conditions":"Kawasaki Disease, Coronary Artery Aneurysm","enrollment":100},{"nctId":"NCT05622500","phase":"NA","title":"Best Endovenous Treatment, Including STenting, Versus Non-endovenous Treatment in Chronic Proximal Deep Venous Disease","status":"TERMINATED","sponsor":"Imperial College London","startDate":"2022-09-03","conditions":"Chronic Venous Insufficiency, Chronic Venous Thrombosis, Iliac Vein Stenosis","enrollment":12},{"nctId":"NCT06983795","phase":"","title":"Pioneering Advancements in Cardiocerebrovascular Interactions in the Asia pacFIC - Patent Foramen Ovale Study","status":"NOT_YET_RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2025-07","conditions":"Ischemic Stroke, Patent Foramen Ovale","enrollment":1000},{"nctId":"NCT06449469","phase":"NA","title":"The Nordic Aortic Valve Intervention Trial 4 (NOTION-4)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2021-05-01","conditions":"Aortic Valve Stenosis, Cardiovascular Diseases, Heart Diseases","enrollment":352},{"nctId":"NCT06715007","phase":"","title":"Antiplatelet Therapy and Endothelial-stabilizing Agents in Cerebral Small Vessel Diseases","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-12-20","conditions":"Stroke, Ischemic, Small Vessel Cerebrovascular Disease, White Matter Hyperintensity","enrollment":300},{"nctId":"NCT06873321","phase":"PHASE4","title":"VTE Incidence After Rivaroxaban + Aspirin or SAPT After Lower-limb Revascularization","status":"RECRUITING","sponsor":"Science Valley Research Institute","startDate":"2024-02-24","conditions":"Peripheral Arterial Disease, Venous Thormboembolism, Cardiovascular Diseases","enrollment":100},{"nctId":"NCT05353140","phase":"NA","title":"LAAO Versus NOAC in Patients with AF and PCI","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2022-09-01","conditions":"Atrial Fibrillation, Percutaneous Coronary Intervention","enrollment":1386},{"nctId":"NCT03062319","phase":"PHASE4","title":"Optimal Antithrombotic Therapy in Ischemic Stroke Patients with Non-Valvular Atrial Fibrillation and Atherothrombosis","status":"TERMINATED","sponsor":"National Hospital Organization Osaka National Hospital","startDate":"2017-04-06","conditions":"Ischemic Stroke, Atrial Fibrillation, Atherothrombosis","enrollment":321},{"nctId":"NCT05077683","phase":"PHASE3","title":"Direct Oral Anticoagulants for Prevention of lEft ventRIcular Thrombus After Anterior Acute Myocardial InFarction - APERITIF","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-10-10","conditions":"Myocardial Infarction, Acute, Left Ventricular Thrombus","enrollment":560},{"nctId":"NCT04847752","phase":"","title":"Study of Predictive Factors Related to Prognosis of Patients With Ischemic Stroke Due to Large-artery Atherosclerosis","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2021-03-01","conditions":"Ischemic Stroke, Large-Artery Atherosclerosis (Embolus/Thrombosis)","enrollment":1000},{"nctId":"NCT06013020","phase":"PHASE4","title":"Century Clot-Guided Prophylactic Rivaroxaban for Post STEMI Complicating Left Ventricular Thrombus","status":"RECRUITING","sponsor":"Zunyi Medical College","startDate":"2024-04-01","conditions":"STEMI - ST Elevation Myocardial Infarction","enrollment":374},{"nctId":"NCT06058130","phase":"NA","title":"Combination of Antiplatelet and Anticoagulation for AIS Patients Witn Concomitant NVAF and Extracranial/Intracranial Artery Stenosis","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-09-29","conditions":"Acute Ischemic Stroke, Atrial Fibrillation, Stenosis, Carotid","enrollment":2171},{"nctId":"NCT05638867","phase":"PHASE4","title":"NOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI","status":"RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2023-11-25","conditions":"Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndrome","enrollment":3944},{"nctId":"NCT04925219","phase":"NA","title":"REmotely Supervised Exercise Therapy Trial 2","status":"UNKNOWN","sponsor":"Mid and South Essex NHS Foundation Trust","startDate":"2021-06-01","conditions":"Claudication, Intermittent, Peripheral Arterial Disease","enrollment":40},{"nctId":"NCT05700266","phase":"PHASE2, PHASE3","title":"Anticoagulation Using Rivaroxaban on Top of Aspirin in Intracranial Atherosclerotic Stenosis","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2023-12-30","conditions":"Ischemic Stroke, Intracranial Atherosclerosis, Stenosis","enrollment":1180},{"nctId":"NCT05960721","phase":"NA","title":"Low-dose NOAC Versus GDMT After LAAO","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2023-07-06","conditions":"Atrial Fibrillation","enrollment":4220},{"nctId":"NCT03764241","phase":"PHASE3","title":"Treatment of Post-STEMI Left Ventricular Thrombus With Optimized Anticoagulant","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2020-02-01","conditions":"ST Segment Elevation Myocardial Infarction, Left Ventricular Thrombus","enrollment":280},{"nctId":"NCT04006288","phase":"PHASE4","title":"Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease","status":"COMPLETED","sponsor":"University of Florida","startDate":"2019-09-06","conditions":"Coronary Artery Disease","enrollment":90},{"nctId":"NCT05705089","phase":"PHASE3","title":"Rivaroxaban vErsus Warfarin for Antithrombotic TheRapy in Patients With LeFt Ventricular Thrombus After Acute STEMI","status":"COMPLETED","sponsor":"Rajaie Cardiovascular Medical and Research Center","startDate":"2020-07-30","conditions":"Left Ventricular Thrombus, ST Segment Elevation Myocardial Infarction","enrollment":50},{"nctId":"NCT05744804","phase":"NA","title":"Efficacy and Safety of Low Dose Rivaroxaban in Patients With Anterior Myocardial Infarction","status":"UNKNOWN","sponsor":"Sohag University","startDate":"2023-03-01","conditions":"Patient With Anterior Myocardial Infarction","enrollment":150},{"nctId":"NCT05718531","phase":"PHASE3","title":"Coronary Artery Ectasia, Efficacy of Various Anti Thrombotic Regimens.","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2023-02-01","conditions":"Coronary Artery Ectasia","enrollment":200},{"nctId":"NCT04333407","phase":"NA","title":"Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.","status":"TERMINATED","sponsor":"Imperial College London","startDate":"2020-04-03","conditions":"COVID-19","enrollment":320},{"nctId":"NCT05546320","phase":"PHASE4","title":"Comparison of the Effect of Medication Therapy in Alleviating Migraine With Patent Foramen Ovale","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences, Fuwai Hospital","startDate":"2022-10-15","conditions":"Patent Foramen Ovale, Migraine","enrollment":1000},{"nctId":"NCT05671276","phase":"PHASE4","title":"Efficacy of Different Anti-Thrombotic Strategies on the Incidence of Silent Cerebral Embolism After Percutaneous Left Atrial Appendage Occlusion","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-02-01","conditions":"Atrial Fibrillation, Left Atrial Appendage Occlusion, Silent Cerebral Embolism","enrollment":150},{"nctId":"NCT04135677","phase":"PHASE4","title":"Clinical Outcomes Between Anticoagulation and DAPT Therapy in AF Patients Successfully Undergoing LAAO","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2022-11-11","conditions":"Left Atrial Appendage Thrombosis, Thrombi, Stroke","enrollment":826},{"nctId":"NCT05573958","phase":"PHASE4","title":"To Assess the Efficacy and Safety of Dual Anticoagulants i.e. Rivaroxaban Plus Aspirin and Clopidogrel Plus Aspirin in Patients Suffering From an Acute Coronary Syndrome","status":"UNKNOWN","sponsor":"Sarmad Zahoor","startDate":"2022-10-01","conditions":"Acute Coronary Syndrome","enrollment":90},{"nctId":"NCT03942913","phase":"","title":"Prospective Real-world Registry Describing Treatment Regimens","status":"UNKNOWN","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2019-10-10","conditions":"Subject Under Anticoagulant","enrollment":573},{"nctId":"NCT03718429","phase":"PHASE4","title":"Pharmacodynamic Effects of Low-dose Rivaroxaban With Antiplatelet Therapies","status":"COMPLETED","sponsor":"University of Florida","startDate":"2019-01-14","conditions":"Coronary Artery Disease, Peripheral Arterial Disease, Atrial Fibrillation","enrollment":86},{"nctId":"NCT04619927","phase":"PHASE4","title":"Genotype-guided Strategy for Antithrombotic Treatment in Peripheral Arterial Disease.","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2021-03-01","conditions":"Peripheral Arterial Disease","enrollment":2276},{"nctId":"NCT05233124","phase":"PHASE2","title":"Antithrombotic Therapy in Acute Coronary Syndromes and Coronary Artery Ectasia","status":"UNKNOWN","sponsor":"Instituto Nacional de Cardiologia Ignacio Chavez","startDate":"2021-09-01","conditions":"Acute Coronary Syndrome, Coronary Artery Ectasia","enrollment":60},{"nctId":"NCT03273322","phase":"PHASE2, PHASE3","title":"Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-09-13","conditions":"Atrial Fibrillation, Atrial Appendage, Hemorrhage","enrollment":105},{"nctId":"NCT01947959","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Germany)","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-12-22","conditions":"Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation","enrollment":665533},{"nctId":"NCT02468102","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-06-15","conditions":"Acute Coronary Syndrome, Venous Thrombosis, Pulmonary Embolism","enrollment":99999},{"nctId":"NCT01947985","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-02-01","conditions":"Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation","enrollment":208958},{"nctId":"NCT01947998","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-12-22","conditions":"Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation","enrollment":50299},{"nctId":"NCT04805710","phase":"PHASE4","title":"Rivaroxaban or Aspirin in Patients With CHD & GD Undergoing PCI","status":"UNKNOWN","sponsor":"Shenyang Northern Hospital","startDate":"2021-03-17","conditions":"Rivaroxaban","enrollment":1020},{"nctId":"NCT04518735","phase":"","title":"Evolution of COVID-19 in Anticoagulated or Antiaggregated Patients (CORONA Study)","status":"COMPLETED","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2020-04-01","conditions":"Covid19","enrollment":1707},{"nctId":"NCT04291287","phase":"","title":"Triple or Dual Antithrombotic Therapy After PCI (TRIDUAL-PCI) Coronary Intervention in Patients With Non-valvular Atrial Fibrillation. Real-world Italian Multicenter Registry (TRIDUAL-PCI)","status":"UNKNOWN","sponsor":"Scientific Institute San Raffaele","startDate":"2020-01-25","conditions":"Atrial Fibrillation, Myocardial Infarction, Anticoagulant-induced Bleeding","enrollment":1500},{"nctId":"NCT02635230","phase":"","title":"What is the Optimal antiplatElet and Anticoagulant Therapy in Patients With Oral Anticoagulation Undergoing revasculariSaTion 2.","status":"UNKNOWN","sponsor":"R&D Cardiologie","startDate":"2014-06","conditions":"Atrial Fibrillations, Heart Valve Prostheses, Acute Coronary Syndromes","enrollment":2200},{"nctId":"NCT03775746","phase":"PHASE4","title":"Can Very Low Dose Rivaroxaban in Addition to Dual Antiplatelet Therapy (DAPT) Improve Thrombotic Status in Acute Coronray Syndrome (ACS) ACS","status":"UNKNOWN","sponsor":"East and North Hertfordshire NHS Trust","startDate":"2019-01-08","conditions":"Acute Coronary Syndrome","enrollment":150},{"nctId":"NCT02833948","phase":"PHASE3","title":"Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)","status":"COMPLETED","sponsor":"ECRI bv","startDate":"2016-05","conditions":"Aortic Valve Stenosis, Cardiovascular Diseases, Heart Valve Diseases","enrollment":231},{"nctId":"NCT02556203","phase":"PHASE3","title":"Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes","status":"TERMINATED","sponsor":"Bayer","startDate":"2015-12-16","conditions":"Transcatheter Aortic Valve Replacement","enrollment":1653},{"nctId":"NCT02260622","phase":"PHASE2","title":"Pilot Study to Examine the Use of Rivaroxaban After Angioplasty for Critical Limb Ischemia","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2014-10","conditions":"Critical Limb Ischemia","enrollment":20},{"nctId":"NCT03786757","phase":"PHASE3","title":"Prevention of Post-STEMI Left Ventricular Thrombus With Optimized Anticoagulant (EARLYmyo-LVT Ⅱ)","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2019-04-01","conditions":"ST Segment Elevation Myocardial Infarction, Left Ventricular Thrombus","enrollment":200},{"nctId":"NCT01962545","phase":"PHASE4","title":"Optimizing Antithrombotic Care in Patients With AtriaL fibrillatiON and Coronary stEnt (OAC-ALONE) Study","status":"COMPLETED","sponsor":"Satoshi Shizuta","startDate":"2013-11-05","conditions":"Atrial Fibrillation, Coronary Artery Disease","enrollment":690},{"nctId":"NCT03481257","phase":"","title":"Comparison Between Ticagrelor Versus Very Low Dose Rivaroxaban With Clopidogrel","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2017-04-12","conditions":"Acute Coronary Syndrome, Acute Myocardial Infarction, Unstable Angina","enrollment":56},{"nctId":"NCT02293395","phase":"PHASE2","title":"A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-04-20","conditions":"Acute Coronary Syndrome","enrollment":3037},{"nctId":"NCT00562289","phase":"PHASE3","title":"Patent Foramen Ovale Closure or Anticoagulants Versus Antiplatelet Therapy to Prevent Stroke Recurrence","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2007-12","conditions":"Ischemic Stroke, Patent Foramen Ovale, Atrial Septal Aneurysm","enrollment":664},{"nctId":"NCT01830543","phase":"PHASE3","title":"A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2013-05-10","conditions":"Atrial Fibrillation, Percutaneous Coronary Intervention","enrollment":2124},{"nctId":"NCT02642419","phase":"PHASE4","title":"Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study","status":"UNKNOWN","sponsor":"Japan Cardiovascular Research Foundation","startDate":"2015-01","conditions":"Atrial Fibrillation","enrollment":2200},{"nctId":"NCT02334254","phase":"PHASE4","title":"Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention","status":"UNKNOWN","sponsor":"Beijing Anzhen Hospital","startDate":"2013-08","conditions":"Atrial Fibrillation","enrollment":420},{"nctId":"NCT02309970","phase":"","title":"Perfusion Computer Tomography: Imaging and Clinical Validation Following Reperfusion Therapy in Acute Ischaemic Stroke","status":"UNKNOWN","sponsor":"Rabin Medical Center","startDate":"2014-12","conditions":"Ischemic Stroke","enrollment":90},{"nctId":"NCT00809965","phase":"PHASE3","title":"An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2008-11","conditions":"Acute Coronary Syndrome, Myocardial Infarction, Myocardial Ischemia","enrollment":15526},{"nctId":"NCT00402597","phase":"PHASE2","title":"Rivaroxaban in Combination With Aspirin Alone or With Aspirin and a Thienopyridine in Patients With Acute Coronary Syndromes (The ATLAS ACS TIMI 46 Trial)","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2006-11","conditions":"Acute Coronary Syndrome","enrollment":3490}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Triple Antithrombotic Therapy"],"phase":"marketed","status":"active","brandName":"Aspirin + Clopidogrel + Rivaroxaban","genericName":"Aspirin + Clopidogrel + Rivaroxaban","companyName":"China National Center for Cardiovascular Diseases","companyId":"china-national-center-for-cardiovascular-diseases","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This triple anticoagulant/antiplatelet combination inhibits blood clotting through multiple pathways: aspirin and clopidogrel block platelet aggregation, while rivaroxaban inhibits Factor Xa in the coagulation cascade. Used for Acute coronary syndrome with high thrombotic risk, Secondary prevention of cardiovascular events in post-acute coronary syndrome patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}